Glatiramer acetate treatment does not modify the clinical course of (NZB × BXSB)F1 lupus murine model

International Immunology

Volumn 20, Issue 10, 2008, Pages 1313-1319

  Borel, Paula ^a   Benkhoucha, Mahdia ^a,b   Weber, Martin S ^c,d   Zamvil, Scott S ^c   Santiago raber, Marie Laure ^a   Lalive, Patrice H ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

(NZB x BXSB)F1 lupus prone animal model; Copaxone ; Experimental autoimmune encephalitis; Systemic lupus erythematosus; Y chromosome associated accelerator

Indexed keywords

DOUBLE STRANDED DNA ANTIBODY; ERYTHROCYTE ANTIBODY; GLATIRAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; FEMALE; HEMATOCRIT; IMMUNOLOGICAL PARAMETERS; MALE; MONOCYTOSIS; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; CHROMATIN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENETIC DISEASES, Y-LINKED; HEMATOCRIT; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NZB; PEPTIDES;

EID: 52949130677     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxn086     Document Type: Article

References (49)

1. Johnson, K. P., Brooks, B. R., Cohen, J. A. et al. 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268.
2. Lisak, R. P., Zweiman, B., Blanchard, N. and Rorke, L. B. 1983. Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE). J. Neurol. Sci. 62:281.
3. Teitelbaum D., Fridkis-Hareli, M., Arnon, R. and Sela, M. 1996. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64:209.
4. Teitelbaum, D., Meshorer, A., Hirshfeld, T., Arnon, R. and Sela, M. 1971. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1:242.
5. Teitelbaum, D., Webb, C., Bree, M., Meshorer, A., Arnon, R. and Sela, M. 1974. Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. Clin. Immunol. Immunopathol. 3:256.
6. Neuhaus, O., Farina, C., Wekerle, H. and Hohlfeld, R. 2001. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56:702.
7. Weber, M. S., Hohlfeld, R. and Zamvil, S. S. 2007. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 4:647.
8. Duda, P. W., Schmied, M. C., Cook, S. L., Krieger, J. I. and Hafler, D. A. 2000. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 105:967.
9. Neuhaus, O., Farina, C., Yassouridis, A. et al. 2000. Multiple sclerosis: Comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl Acad. Sci. USA 97:7452.
10. Vieira, P. L.. Heystek, H. C., Wormmeester, J., Wierenga, E. A. and Kapsenberg, M. L. 2003. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J. Immunol. 170:4483.
11. Karandikar, N. J., Crawford, M. P., Yan, X. et al. 2002. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J. Clin. Invest. 109:641.
12. Weber, M. S., Starck, M., Wagenpfeil, S., Meinl, E., Hohlfeld, R. and Farina, C. 2004. Multiple sclerosis: Glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 127:1370.
13. Weber, M. S., Prod'homme, T., Youssef, S. et al. 2007. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 13:935.
14. Kotzin, B. L. 1996. Systemic lupus erythematosus. Cell 85:303.
15. Shlomchik, M. J., Craft, J. E. and Mamula, M. J. 2001. From T to B and back again: Positive feedback in systemic autoimmune disease. Nat. Rev. Immunol. 1:147.
16. Vyse, T. J. and Kotzin, B. L. 1996. Genetic basis of systemic lupus erythematosus. Curr. Opin. Immunol. 8:843.
17. Kono, D. H. and Theofilopoulos, A. N. 1996. Genetic contributions to SLE. J. Autoimmun. 9:437.
18. Morel, L., Rudofsky, U. H., Longmate, J. A., Schiffenbauer, J. and Wakeland, E. K. 1994. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1:219.
19. Izui, S., Iwamoto, M., Fossati, L., Merino, R., Takahashi, S. and Ibnou-Zekri, N. 1995. The Yaa gene model of systemic lupus erythematosus. Immunol. Rev. 144:137.
20. Merino, R., Iwamoto, M., Gershwin, M. E. and Izui, S. 1994. The Yaa gene abrogates the major histocompatibility complex association of murine lupus in (NZB x BXSB)F1 hybrid mice. J. Clin. Invest. 94:521.
21. Pisitkun, P., Deane, J. A., Difilippantonio, M. J., Tarasenko, T., Satterthwaite, A. B. and Bolland, S. 2006. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312:1669.
22. Subramanian, S., Tus, K., Li, Q. Z. et al. 2006. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl Acad. Sci. USA 103:9970.
23. Izui, S., McConahey, P. J., Theofilopoulos, A. N. and Dixon, F. J. 1979. Association of circulating retroviral gp70-anti-gp70 immune complexes with murine systemic lupus erythematosus. J. Exp. Med. 149:1099.
24. Wofsy, D., Kerger, C. E. and Seaman, W. E. 1984. Monocytosis in the BXSB model for systemic lupus erythematosus. J. Exp. Med. 159:629.
25. Kikuchi, S., Santiago-Raber, M. L., Amano, H. et al. 2006. Contribution of NZB autoimmunity 2 to Y-linked autoimmune acceleration-induced monocytosis in association with murine systemic lupus. J. Immunol. 176:3240.
26. Amano, H., Amano, E., Santiago-Raber, M. L. et al. 2005. Selective expansion of a monocyte subset expressing the CD11c dendritic cell marker in the Yaa model of systemic lupus erythematosus. Arthritis Rheum. 52:2790.
27. Rozzo, S. J., Allard, J. D., Choubey, D. et al. 2001. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 15:435.
28. Luzuy, S., Merino, J., Engers, H., Izui, S. and Lambert, P. H. 1986. Autoimmunity after induction of neonatal tolerance to alloantigens: Role of B cell chimerism and F1 donor B cell activation. J. Immunol. 136:4420.
29. Izui, S., Higaki, M., Morrow, D. and Merino, R. 1988. The Y chromosome from autoimmune BXSB/MpJ mice induces a lupus-like syndrome in (NZW x C57BL/6)F1 male mice, but not in C57BL/6 male mice. Eur. J. Immunol. 18:911.
30. Baudino, L., Fossati-Jimack, L., Chevalley, C., Martinez-Soria, E., Shulman, M. J. and Izui, S. 2007. IgM and IgA anti-erythrocyte autoantibodies induce anemia in a mouse model through multivalency-dependent hemagglutination but not through complement activation. Blood 109:5355.
31. Caulfield, M. J., Stanko, D. and Calkins, C. 1989. Characterization of the spontaneous autoimmune (anti-erythrocyte) response in NZB mice using a pathogenic monoclonal autoantibody and its anti-idiotype. Immunology 66:233.
32. Crispin, J. C. and Alcocer-Varela, J. 2007. The role myeloid dendritic cells play in the pathogenesis of systemic lupus erythematosus. Autoimmun. Rev. 6:450.
33. Hoffman, R. W. 2004. T cells in the pathogenesis of systemic lupus erythematosus. Clin. Immunol. 113:4.
34. Sospedra, M. and Martin, R. 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23:683.
35. Stuve, O., Cepok, S., Elias, B. et al. 2005. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch. Neurol. 62:1620.
36. Tanaka, Y., Yamamoto, K., Takeuchi, T. et al. 2007. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod. Rheumatol. 17:191.
37. Hauser, S. L., Waubant, E., Arnold, D. L. et al. 2008. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358:676.
38. Lucchinetti, C., Bruck, W., Parisi, J., Scheithauer, B., Rodriguez, M. and Lassmann, H. 2000. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47:707.
39. Fossati, L., Sobel, E. S., Iwamoto, M., Cohen, P. L., Eisenberg, R. A. and Izui, S. 1995. The Yaa gene-mediated acceleration of murine lupus: Yaa- T cells from non-autoimmune mice collaborate with Yaa+ B cells to produce lupus autoantibodies in vivo. Eur. J. Immunol. 25:3412.
40. Murphy, E. D. and Roths, J. B. 1979. A Y chromosome associated factor in strain BXSB producing accelerated autoimmunity and lymphoproliferation. Arthritis Rheum. 22:1188.
41. Fisher, C. L., Eisenberg, R. A. and Cohen, P. L. 1988. Quantitation and IgG subclass distribution of antichromatin autoantibodies in SLE mice. Clin. Immunol. Immunopathol. 46:205.
42. Goldman, M., Druet, P. and Gleichmann, E. 1991. TH2 cells in systemic autoimmunity: Insights from allogeneic diseases and chemically-induced autoimmunity. Immunol. Today 12:223.
43. Santiago-Raber, M. L., Laporte, C., Reininger, L. and Izui, S. 2004. Genetic basis of murine lupus. Autoimmun. Rev. 3:33.
44. Theofilopoulos, A. N. and Dixon, F. J. 1985. Murine models of systemic lupus erythematosus. Adv. Immunol. 37:269.
45. Zhang, M., Chan, C. C., Vistica, B., Hung, V., Wiggert, B. and Gery, I. 2000. Copolymer 1 inhibits experimental autoimmune uveoretinitis. J. Neuroimmunol. 103:189.
46. Gur, C., Karussis, D., Golden, E., Doron, S., Ilan, Y. and Safadi, R. 2006. Amelioration of experimental colitis by Copaxone is associated with class-II-restricted CD4 immune blocking. Clin. Immunol. 118:307.
47. Arnon, R. and Aharoni, R. 2004. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc. Natl Acad. Sci. USA 101 (Suppl. 2):14593.
48. Butovsky, O., Koronyo-Hamaoui, M., Kunis, G. et al. 2006. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc. Natl Acad. Sci. USA 103:11784.
49. Frenkel, D., Maron, R., Burt, D. S. and Weiner, H. L. 2005. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest. 115:2423.